Comparing Imetelstat With Other Treatments in Low-Risk MDS
March 27th 2024Amer Zeidan, MBBS, discusses how imetelstat compares with other treatments for patients with low-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.
Watch
Risk/Benefits of Managing AEs with Combination Therapy
March 26th 2024Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.
Watch
Niraparib With Abiraterone Boosts Survival in BRCA-Mutated Prostate Cancer
March 24th 2024Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.
Watch
Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies
March 22nd 2024Virginia Kaklamani, MD, DSc, explores strategies for mitigating fatigue, nausea, vomiting, and other toxicities and adverse events that may arise when patients receive endocrine therapy in combination with CDK4/6 inhibitors.
Watch
EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection
March 22nd 2024Virginia Kaklamani, MD, DSc, discusses the impact of the Phase III EMERALD trial results on the treatment landscape of HR+/HER2-low metastatic breast cancer, emphasizing the importance of selecting optimal drug combinations while minimizing toxicity profiles.
Watch
Virginia Kaklamani, MD, DSc, presents a case of metastatic breast cancer, initially responsive to first-line aromatase and CDK4/6 inhibitors, that progressed after 32 months. She explores using biomarker testing to identify ESR1 and other actionable mutations potentially causing endocrine resistance, guiding the transition to second-line therapy.
Watch